nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—ALB—Vandetanib—thyroid cancer	0.147	0.392	CbGbCtD
Furosemide—ABCC2—Sorafenib—thyroid cancer	0.142	0.379	CbGbCtD
Furosemide—ABCC2—Doxorubicin—thyroid cancer	0.0865	0.23	CbGbCtD
Furosemide—CA6—saliva-secreting gland—thyroid cancer	0.00865	0.0616	CbGeAlD
Furosemide—SLCO2A1—neck—thyroid cancer	0.0079	0.0563	CbGeAlD
Furosemide—PGD—neck—thyroid cancer	0.00704	0.0502	CbGeAlD
Furosemide—CA7—trachea—thyroid cancer	0.00689	0.0491	CbGeAlD
Furosemide—SLCO2A1—saliva-secreting gland—thyroid cancer	0.00616	0.0439	CbGeAlD
Furosemide—PGD—saliva-secreting gland—thyroid cancer	0.00549	0.0391	CbGeAlD
Furosemide—SLCO2A1—trachea—thyroid cancer	0.00475	0.0339	CbGeAlD
Furosemide—CA6—head—thyroid cancer	0.00468	0.0334	CbGeAlD
Furosemide—CA4—neck—thyroid cancer	0.0046	0.0328	CbGeAlD
Furosemide—CA12—trachea—thyroid cancer	0.00447	0.0319	CbGeAlD
Furosemide—PGD—trachea—thyroid cancer	0.00424	0.0302	CbGeAlD
Furosemide—CA2—neck—thyroid cancer	0.00382	0.0272	CbGeAlD
Furosemide—SLCO2A1—thyroid gland—thyroid cancer	0.00376	0.0268	CbGeAlD
Furosemide—SLC12A1—head—thyroid cancer	0.00361	0.0258	CbGeAlD
Furosemide—CA4—saliva-secreting gland—thyroid cancer	0.00359	0.0256	CbGeAlD
Furosemide—PGD—thyroid gland—thyroid cancer	0.00335	0.0239	CbGeAlD
Furosemide—SLCO2A1—head—thyroid cancer	0.00334	0.0238	CbGeAlD
Furosemide—CA5B—thyroid gland—thyroid cancer	0.00317	0.0226	CbGeAlD
Furosemide—CA12—head—thyroid cancer	0.00314	0.0224	CbGeAlD
Furosemide—CA2—saliva-secreting gland—thyroid cancer	0.00298	0.0212	CbGeAlD
Furosemide—PGD—head—thyroid cancer	0.00297	0.0212	CbGeAlD
Furosemide—SLC22A5—saliva-secreting gland—thyroid cancer	0.00293	0.0209	CbGeAlD
Furosemide—CA5B—head—thyroid cancer	0.00282	0.0201	CbGeAlD
Furosemide—CA4—trachea—thyroid cancer	0.00277	0.0197	CbGeAlD
Furosemide—CA1—head—thyroid cancer	0.00249	0.0177	CbGeAlD
Furosemide—SLCO2A1—lymph node—thyroid cancer	0.00234	0.0166	CbGeAlD
Furosemide—CA2—trachea—thyroid cancer	0.0023	0.0164	CbGeAlD
Furosemide—SLC22A5—trachea—thyroid cancer	0.00226	0.0161	CbGeAlD
Furosemide—CA4—thyroid gland—thyroid cancer	0.00219	0.0156	CbGeAlD
Furosemide—SLC22A8—head—thyroid cancer	0.0021	0.015	CbGeAlD
Furosemide—PGD—lymph node—thyroid cancer	0.00208	0.0148	CbGeAlD
Furosemide—CA5B—lymph node—thyroid cancer	0.00197	0.0141	CbGeAlD
Furosemide—Renal failure—Sorafenib—thyroid cancer	0.00195	0.00497	CcSEcCtD
Furosemide—CA4—head—thyroid cancer	0.00194	0.0139	CbGeAlD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00194	0.00495	CcSEcCtD
Furosemide—Dry mouth—Vandetanib—thyroid cancer	0.00191	0.00488	CcSEcCtD
Furosemide—Hypomagnesaemia—Doxorubicin—thyroid cancer	0.00191	0.00487	CcSEcCtD
Furosemide—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00187	0.00478	CcSEcCtD
Furosemide—Thrombosis—Epirubicin—thyroid cancer	0.00185	0.00472	CcSEcCtD
Furosemide—Nervous system disorder—Vandetanib—thyroid cancer	0.00184	0.00469	CcSEcCtD
Furosemide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00183	0.00468	CcSEcCtD
Furosemide—Skin disorder—Vandetanib—thyroid cancer	0.00182	0.00464	CcSEcCtD
Furosemide—CA2—thyroid gland—thyroid cancer	0.00182	0.0129	CbGeAlD
Furosemide—Blister—Epirubicin—thyroid cancer	0.00182	0.00463	CcSEcCtD
Furosemide—SLC22A5—thyroid gland—thyroid cancer	0.00179	0.0127	CbGeAlD
Furosemide—Urinary tract disorder—Sorafenib—thyroid cancer	0.00176	0.00448	CcSEcCtD
Furosemide—Bumetanide—PTGS2—thyroid cancer	0.00175	1	CrCbGaD
Furosemide—Urethral disorder—Sorafenib—thyroid cancer	0.00174	0.00445	CcSEcCtD
Furosemide—CA1—lymph node—thyroid cancer	0.00174	0.0124	CbGeAlD
Furosemide—Thrombosis—Doxorubicin—thyroid cancer	0.00171	0.00437	CcSEcCtD
Furosemide—Paraesthesia—Vandetanib—thyroid cancer	0.00168	0.00429	CcSEcCtD
Furosemide—Erythema multiforme—Sorafenib—thyroid cancer	0.00168	0.00429	CcSEcCtD
Furosemide—Blister—Doxorubicin—thyroid cancer	0.00168	0.00429	CcSEcCtD
Furosemide—Tinnitus—Sorafenib—thyroid cancer	0.00166	0.00423	CcSEcCtD
Furosemide—Decreased appetite—Vandetanib—thyroid cancer	0.00163	0.00416	CcSEcCtD
Furosemide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00162	0.00413	CcSEcCtD
Furosemide—Glycosuria—Epirubicin—thyroid cancer	0.00162	0.00412	CcSEcCtD
Furosemide—Fatigue—Vandetanib—thyroid cancer	0.00161	0.00412	CcSEcCtD
Furosemide—Angiopathy—Sorafenib—thyroid cancer	0.00161	0.00412	CcSEcCtD
Furosemide—CA2—head—thyroid cancer	0.00161	0.0115	CbGeAlD
Furosemide—Immune system disorder—Sorafenib—thyroid cancer	0.00161	0.0041	CcSEcCtD
Furosemide—Injection site pain—Epirubicin—thyroid cancer	0.0016	0.00409	CcSEcCtD
Furosemide—Pain—Vandetanib—thyroid cancer	0.0016	0.00409	CcSEcCtD
Furosemide—Constipation—Vandetanib—thyroid cancer	0.0016	0.00409	CcSEcCtD
Furosemide—Arrhythmia—Sorafenib—thyroid cancer	0.00159	0.00405	CcSEcCtD
Furosemide—Erythema—Sorafenib—thyroid cancer	0.00155	0.00395	CcSEcCtD
Furosemide—Malnutrition—Sorafenib—thyroid cancer	0.00155	0.00395	CcSEcCtD
Furosemide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00153	0.00391	CcSEcCtD
Furosemide—ALB—lymph node—thyroid cancer	0.00153	0.0109	CbGeAlD
Furosemide—Dysgeusia—Sorafenib—thyroid cancer	0.00152	0.00387	CcSEcCtD
Furosemide—Glycosuria—Doxorubicin—thyroid cancer	0.00149	0.00382	CcSEcCtD
Furosemide—Jaundice cholestatic—Epirubicin—thyroid cancer	0.00149	0.0038	CcSEcCtD
Furosemide—Muscle spasms—Sorafenib—thyroid cancer	0.00149	0.0038	CcSEcCtD
Furosemide—Injection site pain—Doxorubicin—thyroid cancer	0.00148	0.00379	CcSEcCtD
Furosemide—Body temperature increased—Vandetanib—thyroid cancer	0.00148	0.00378	CcSEcCtD
Furosemide—Abdominal pain—Vandetanib—thyroid cancer	0.00148	0.00378	CcSEcCtD
Furosemide—ABCC2—lymph node—thyroid cancer	0.00143	0.0102	CbGeAlD
Furosemide—Anaemia—Sorafenib—thyroid cancer	0.00143	0.00365	CcSEcCtD
Furosemide—Hypocalcaemia—Epirubicin—thyroid cancer	0.00143	0.00365	CcSEcCtD
Furosemide—Hyperuricaemia—Epirubicin—thyroid cancer	0.00141	0.0036	CcSEcCtD
Furosemide—Leukopenia—Sorafenib—thyroid cancer	0.00139	0.00354	CcSEcCtD
Furosemide—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.00138	0.00352	CcSEcCtD
Furosemide—CA4—lymph node—thyroid cancer	0.00136	0.0097	CbGeAlD
Furosemide—Asthenia—Vandetanib—thyroid cancer	0.00134	0.00343	CcSEcCtD
Furosemide—Blood uric acid increased—Epirubicin—thyroid cancer	0.00133	0.0034	CcSEcCtD
Furosemide—Pruritus—Vandetanib—thyroid cancer	0.00133	0.00338	CcSEcCtD
Furosemide—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00132	0.00338	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00131	0.00334	CcSEcCtD
Furosemide—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00131	0.00333	CcSEcCtD
Furosemide—Dry mouth—Sorafenib—thyroid cancer	0.00129	0.00329	CcSEcCtD
Furosemide—Diarrhoea—Vandetanib—thyroid cancer	0.00128	0.00327	CcSEcCtD
Furosemide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00126	0.00322	CcSEcCtD
Furosemide—Shock—Sorafenib—thyroid cancer	0.00124	0.00317	CcSEcCtD
Furosemide—Nervous system disorder—Sorafenib—thyroid cancer	0.00124	0.00316	CcSEcCtD
Furosemide—Dizziness—Vandetanib—thyroid cancer	0.00124	0.00316	CcSEcCtD
Furosemide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00124	0.00316	CcSEcCtD
Furosemide—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00123	0.00315	CcSEcCtD
Furosemide—Aplastic anaemia—Epirubicin—thyroid cancer	0.00123	0.00314	CcSEcCtD
Furosemide—Skin disorder—Sorafenib—thyroid cancer	0.00123	0.00313	CcSEcCtD
Furosemide—Anorexia—Sorafenib—thyroid cancer	0.0012	0.00307	CcSEcCtD
Furosemide—Cramps of lower extremities—Epirubicin—thyroid cancer	0.0012	0.00307	CcSEcCtD
Furosemide—Vomiting—Vandetanib—thyroid cancer	0.00119	0.00304	CcSEcCtD
Furosemide—Bladder pain—Epirubicin—thyroid cancer	0.00118	0.00302	CcSEcCtD
Furosemide—Rash—Vandetanib—thyroid cancer	0.00118	0.00301	CcSEcCtD
Furosemide—Dermatitis—Vandetanib—thyroid cancer	0.00118	0.00301	CcSEcCtD
Furosemide—Headache—Vandetanib—thyroid cancer	0.00117	0.00299	CcSEcCtD
Furosemide—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00114	0.0029	CcSEcCtD
Furosemide—Mental disability—Epirubicin—thyroid cancer	0.00114	0.0029	CcSEcCtD
Furosemide—CA2—lymph node—thyroid cancer	0.00113	0.00804	CbGeAlD
Furosemide—Nausea—Vandetanib—thyroid cancer	0.00111	0.00284	CcSEcCtD
Furosemide—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00111	0.00284	CcSEcCtD
Furosemide—SLC22A5—lymph node—thyroid cancer	0.00111	0.00791	CbGeAlD
Furosemide—Decreased appetite—Sorafenib—thyroid cancer	0.0011	0.0028	CcSEcCtD
Furosemide—Thrombophlebitis—Epirubicin—thyroid cancer	0.0011	0.0028	CcSEcCtD
Furosemide—Bladder pain—Doxorubicin—thyroid cancer	0.00109	0.00279	CcSEcCtD
Furosemide—Diabetes mellitus—Epirubicin—thyroid cancer	0.00109	0.00279	CcSEcCtD
Furosemide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00109	0.00278	CcSEcCtD
Furosemide—Fatigue—Sorafenib—thyroid cancer	0.00109	0.00278	CcSEcCtD
Furosemide—Photosensitivity—Epirubicin—thyroid cancer	0.00108	0.00276	CcSEcCtD
Furosemide—Pain—Sorafenib—thyroid cancer	0.00108	0.00276	CcSEcCtD
Furosemide—Constipation—Sorafenib—thyroid cancer	0.00108	0.00276	CcSEcCtD
Furosemide—Vascular purpura—Epirubicin—thyroid cancer	0.00106	0.00271	CcSEcCtD
Furosemide—Mental disability—Doxorubicin—thyroid cancer	0.00105	0.00268	CcSEcCtD
Furosemide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00103	0.00264	CcSEcCtD
Furosemide—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00102	0.00259	CcSEcCtD
Furosemide—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00101	0.00258	CcSEcCtD
Furosemide—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00101	0.00257	CcSEcCtD
Furosemide—Urticaria—Sorafenib—thyroid cancer	0.001	0.00256	CcSEcCtD
Furosemide—Photosensitivity—Doxorubicin—thyroid cancer	0.001	0.00256	CcSEcCtD
Furosemide—Abdominal pain—Sorafenib—thyroid cancer	0.000999	0.00255	CcSEcCtD
Furosemide—Body temperature increased—Sorafenib—thyroid cancer	0.000999	0.00255	CcSEcCtD
Furosemide—Dermatitis bullous—Epirubicin—thyroid cancer	0.000994	0.00254	CcSEcCtD
Furosemide—Purpura—Epirubicin—thyroid cancer	0.000986	0.00252	CcSEcCtD
Furosemide—Vascular purpura—Doxorubicin—thyroid cancer	0.000983	0.00251	CcSEcCtD
Furosemide—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000981	0.00251	CcSEcCtD
Furosemide—Lethargy—Epirubicin—thyroid cancer	0.000969	0.00247	CcSEcCtD
Furosemide—Hyponatraemia—Epirubicin—thyroid cancer	0.000954	0.00243	CcSEcCtD
Furosemide—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000932	0.00238	CcSEcCtD
Furosemide—Hypersensitivity—Sorafenib—thyroid cancer	0.000931	0.00238	CcSEcCtD
Furosemide—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00092	0.00235	CcSEcCtD
Furosemide—Purpura—Doxorubicin—thyroid cancer	0.000912	0.00233	CcSEcCtD
Furosemide—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000908	0.00232	CcSEcCtD
Furosemide—Asthenia—Sorafenib—thyroid cancer	0.000906	0.00231	CcSEcCtD
Furosemide—Lethargy—Doxorubicin—thyroid cancer	0.000897	0.00229	CcSEcCtD
Furosemide—Pruritus—Sorafenib—thyroid cancer	0.000894	0.00228	CcSEcCtD
Furosemide—Blood creatinine increased—Epirubicin—thyroid cancer	0.00089	0.00227	CcSEcCtD
Furosemide—Dehydration—Epirubicin—thyroid cancer	0.000883	0.00226	CcSEcCtD
Furosemide—Hyponatraemia—Doxorubicin—thyroid cancer	0.000882	0.00225	CcSEcCtD
Furosemide—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000868	0.00221	CcSEcCtD
Furosemide—Hypokalaemia—Epirubicin—thyroid cancer	0.000865	0.00221	CcSEcCtD
Furosemide—Diarrhoea—Sorafenib—thyroid cancer	0.000864	0.00221	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000855	0.00218	CcSEcCtD
Furosemide—Muscular weakness—Epirubicin—thyroid cancer	0.000838	0.00214	CcSEcCtD
Furosemide—Dizziness—Sorafenib—thyroid cancer	0.000835	0.00213	CcSEcCtD
Furosemide—Abdominal distension—Epirubicin—thyroid cancer	0.000827	0.00211	CcSEcCtD
Furosemide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000823	0.0021	CcSEcCtD
Furosemide—Dehydration—Doxorubicin—thyroid cancer	0.000817	0.00209	CcSEcCtD
Furosemide—Eosinophilia—Epirubicin—thyroid cancer	0.000813	0.00208	CcSEcCtD
Furosemide—Pancreatitis—Epirubicin—thyroid cancer	0.000805	0.00205	CcSEcCtD
Furosemide—Vomiting—Sorafenib—thyroid cancer	0.000803	0.00205	CcSEcCtD
Furosemide—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000803	0.00205	CcSEcCtD
Furosemide—Hypokalaemia—Doxorubicin—thyroid cancer	0.0008	0.00204	CcSEcCtD
Furosemide—Rash—Sorafenib—thyroid cancer	0.000797	0.00203	CcSEcCtD
Furosemide—Dermatitis—Sorafenib—thyroid cancer	0.000796	0.00203	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000791	0.00202	CcSEcCtD
Furosemide—Headache—Sorafenib—thyroid cancer	0.000791	0.00202	CcSEcCtD
Furosemide—Muscular weakness—Doxorubicin—thyroid cancer	0.000775	0.00198	CcSEcCtD
Furosemide—Abdominal distension—Doxorubicin—thyroid cancer	0.000765	0.00195	CcSEcCtD
Furosemide—Pollakiuria—Epirubicin—thyroid cancer	0.000758	0.00194	CcSEcCtD
Furosemide—Eosinophilia—Doxorubicin—thyroid cancer	0.000752	0.00192	CcSEcCtD
Furosemide—Nausea—Sorafenib—thyroid cancer	0.00075	0.00192	CcSEcCtD
Furosemide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000749	0.00191	CcSEcCtD
Furosemide—Pancreatitis—Doxorubicin—thyroid cancer	0.000745	0.0019	CcSEcCtD
Furosemide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000741	0.00189	CcSEcCtD
Furosemide—Drowsiness—Epirubicin—thyroid cancer	0.000732	0.00187	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000726	0.00185	CcSEcCtD
Furosemide—Renal failure—Epirubicin—thyroid cancer	0.00072	0.00184	CcSEcCtD
Furosemide—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000704	0.00783	CbGpPWpGaD
Furosemide—Sweating—Epirubicin—thyroid cancer	0.000702	0.00179	CcSEcCtD
Furosemide—Pollakiuria—Doxorubicin—thyroid cancer	0.000702	0.00179	CcSEcCtD
Furosemide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000693	0.00177	CcSEcCtD
Furosemide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000692	0.00177	CcSEcCtD
Furosemide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000685	0.00175	CcSEcCtD
Furosemide—Agranulocytosis—Epirubicin—thyroid cancer	0.000683	0.00174	CcSEcCtD
Furosemide—Drowsiness—Doxorubicin—thyroid cancer	0.000677	0.00173	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000672	0.00171	CcSEcCtD
Furosemide—Renal failure—Doxorubicin—thyroid cancer	0.000666	0.0017	CcSEcCtD
Furosemide—Sweating—Doxorubicin—thyroid cancer	0.000649	0.00166	CcSEcCtD
Furosemide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000649	0.00166	CcSEcCtD
Furosemide—Urethral disorder—Epirubicin—thyroid cancer	0.000644	0.00164	CcSEcCtD
Furosemide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000641	0.00164	CcSEcCtD
Furosemide—Visual impairment—Epirubicin—thyroid cancer	0.000633	0.00162	CcSEcCtD
Furosemide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000632	0.00161	CcSEcCtD
Furosemide—CA14—Metabolism—MINPP1—thyroid cancer	0.000632	0.00703	CbGpPWpGaD
Furosemide—SLC12A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000631	0.00702	CbGpPWpGaD
Furosemide—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000627	0.00697	CbGpPWpGaD
Furosemide—Erythema multiforme—Epirubicin—thyroid cancer	0.000621	0.00159	CcSEcCtD
Furosemide—CA6—Metabolism—MINPP1—thyroid cancer	0.000616	0.00685	CbGpPWpGaD
Furosemide—CA5A—Metabolism—MINPP1—thyroid cancer	0.000616	0.00685	CbGpPWpGaD
Furosemide—Eye disorder—Epirubicin—thyroid cancer	0.000614	0.00157	CcSEcCtD
Furosemide—Tinnitus—Epirubicin—thyroid cancer	0.000613	0.00156	CcSEcCtD
Furosemide—PGD—Disease—TRIM24—thyroid cancer	0.000603	0.00671	CbGpPWpGaD
Furosemide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.0006	0.00153	CcSEcCtD
Furosemide—Angiopathy—Epirubicin—thyroid cancer	0.000596	0.00152	CcSEcCtD
Furosemide—Urethral disorder—Doxorubicin—thyroid cancer	0.000596	0.00152	CcSEcCtD
Furosemide—PGD—Metabolism—MINPP1—thyroid cancer	0.000594	0.00661	CbGpPWpGaD
Furosemide—Immune system disorder—Epirubicin—thyroid cancer	0.000594	0.00152	CcSEcCtD
Furosemide—Arrhythmia—Epirubicin—thyroid cancer	0.000587	0.0015	CcSEcCtD
Furosemide—Visual impairment—Doxorubicin—thyroid cancer	0.000586	0.0015	CcSEcCtD
Furosemide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000575	0.00147	CcSEcCtD
Furosemide—CA5B—Metabolism—MINPP1—thyroid cancer	0.000575	0.00639	CbGpPWpGaD
Furosemide—CA7—Metabolism—MINPP1—thyroid cancer	0.000575	0.00639	CbGpPWpGaD
Furosemide—Malnutrition—Epirubicin—thyroid cancer	0.000572	0.00146	CcSEcCtD
Furosemide—Erythema—Epirubicin—thyroid cancer	0.000572	0.00146	CcSEcCtD
Furosemide—Eye disorder—Doxorubicin—thyroid cancer	0.000568	0.00145	CcSEcCtD
Furosemide—PGD—Disease—CHST14—thyroid cancer	0.000567	0.00631	CbGpPWpGaD
Furosemide—Tinnitus—Doxorubicin—thyroid cancer	0.000567	0.00145	CcSEcCtD
Furosemide—Flatulence—Epirubicin—thyroid cancer	0.000564	0.00144	CcSEcCtD
Furosemide—Dysgeusia—Epirubicin—thyroid cancer	0.00056	0.00143	CcSEcCtD
Furosemide—Angiopathy—Doxorubicin—thyroid cancer	0.000552	0.00141	CcSEcCtD
Furosemide—Muscle spasms—Epirubicin—thyroid cancer	0.00055	0.0014	CcSEcCtD
Furosemide—Immune system disorder—Doxorubicin—thyroid cancer	0.000549	0.0014	CcSEcCtD
Furosemide—Arrhythmia—Doxorubicin—thyroid cancer	0.000543	0.00139	CcSEcCtD
Furosemide—Vision blurred—Epirubicin—thyroid cancer	0.000539	0.00138	CcSEcCtD
Furosemide—PGD—Disease—TRIM33—thyroid cancer	0.000537	0.00598	CbGpPWpGaD
Furosemide—CA14—Metabolism—NDUFA13—thyroid cancer	0.000537	0.00597	CbGpPWpGaD
Furosemide—CA12—Metabolism—MINPP1—thyroid cancer	0.000532	0.00592	CbGpPWpGaD
Furosemide—Malnutrition—Doxorubicin—thyroid cancer	0.000529	0.00135	CcSEcCtD
Furosemide—Erythema—Doxorubicin—thyroid cancer	0.000529	0.00135	CcSEcCtD
Furosemide—Anaemia—Epirubicin—thyroid cancer	0.000529	0.00135	CcSEcCtD
Furosemide—Agitation—Epirubicin—thyroid cancer	0.000526	0.00134	CcSEcCtD
Furosemide—CA6—Metabolism—NDUFA13—thyroid cancer	0.000523	0.00582	CbGpPWpGaD
Furosemide—CA5A—Metabolism—NDUFA13—thyroid cancer	0.000523	0.00582	CbGpPWpGaD
Furosemide—Flatulence—Doxorubicin—thyroid cancer	0.000522	0.00133	CcSEcCtD
Furosemide—Dysgeusia—Doxorubicin—thyroid cancer	0.000518	0.00132	CcSEcCtD
Furosemide—Vertigo—Epirubicin—thyroid cancer	0.000514	0.00131	CcSEcCtD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000513	0.00571	CbGpPWpGaD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000513	0.00571	CbGpPWpGaD
Furosemide—Leukopenia—Epirubicin—thyroid cancer	0.000512	0.00131	CcSEcCtD
Furosemide—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000509	0.00566	CbGpPWpGaD
Furosemide—Muscle spasms—Doxorubicin—thyroid cancer	0.000509	0.0013	CcSEcCtD
Furosemide—PGD—Metabolism—NDUFA13—thyroid cancer	0.000505	0.00562	CbGpPWpGaD
Furosemide—CA14—Metabolism—CHST14—thyroid cancer	0.000505	0.00562	CbGpPWpGaD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000505	0.00561	CbGpPWpGaD
Furosemide—SLC22A11—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000503	0.00559	CbGpPWpGaD
Furosemide—SLC22A11—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000503	0.00559	CbGpPWpGaD
Furosemide—Vision blurred—Doxorubicin—thyroid cancer	0.000499	0.00127	CcSEcCtD
Furosemide—CA6—Metabolism—CHST14—thyroid cancer	0.000492	0.00547	CbGpPWpGaD
Furosemide—CA5A—Metabolism—CHST14—thyroid cancer	0.000492	0.00547	CbGpPWpGaD
Furosemide—Anaemia—Doxorubicin—thyroid cancer	0.000489	0.00125	CcSEcCtD
Furosemide—CA5B—Metabolism—NDUFA13—thyroid cancer	0.000489	0.00543	CbGpPWpGaD
Furosemide—CA7—Metabolism—NDUFA13—thyroid cancer	0.000489	0.00543	CbGpPWpGaD
Furosemide—Agitation—Doxorubicin—thyroid cancer	0.000486	0.00124	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000484	0.00123	CcSEcCtD
Furosemide—Dry mouth—Epirubicin—thyroid cancer	0.000476	0.00122	CcSEcCtD
Furosemide—Vertigo—Doxorubicin—thyroid cancer	0.000476	0.00121	CcSEcCtD
Furosemide—PGD—Metabolism—CHST14—thyroid cancer	0.000475	0.00528	CbGpPWpGaD
Furosemide—Leukopenia—Doxorubicin—thyroid cancer	0.000474	0.00121	CcSEcCtD
Furosemide—Confusional state—Epirubicin—thyroid cancer	0.000471	0.0012	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000468	0.00521	CbGpPWpGaD
Furosemide—Anaphylactic shock—Epirubicin—thyroid cancer	0.000467	0.00119	CcSEcCtD
Furosemide—CA5B—Metabolism—CHST14—thyroid cancer	0.000459	0.00511	CbGpPWpGaD
Furosemide—CA7—Metabolism—CHST14—thyroid cancer	0.000459	0.00511	CbGpPWpGaD
Furosemide—Shock—Epirubicin—thyroid cancer	0.000459	0.00117	CcSEcCtD
Furosemide—Nervous system disorder—Epirubicin—thyroid cancer	0.000458	0.00117	CcSEcCtD
Furosemide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000457	0.00117	CcSEcCtD
Furosemide—Skin disorder—Epirubicin—thyroid cancer	0.000454	0.00116	CcSEcCtD
Furosemide—CA12—Metabolism—NDUFA13—thyroid cancer	0.000453	0.00504	CbGpPWpGaD
Furosemide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000451	0.00115	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000448	0.00114	CcSEcCtD
Furosemide—Anorexia—Epirubicin—thyroid cancer	0.000445	0.00114	CcSEcCtD
Furosemide—Dry mouth—Doxorubicin—thyroid cancer	0.000441	0.00113	CcSEcCtD
Furosemide—Hypotension—Epirubicin—thyroid cancer	0.000436	0.00111	CcSEcCtD
Furosemide—Confusional state—Doxorubicin—thyroid cancer	0.000436	0.00111	CcSEcCtD
Furosemide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000432	0.0011	CcSEcCtD
Furosemide—SLC12A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000428	0.00476	CbGpPWpGaD
Furosemide—SLC12A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000428	0.00476	CbGpPWpGaD
Furosemide—CA12—Metabolism—CHST14—thyroid cancer	0.000426	0.00473	CbGpPWpGaD
Furosemide—Shock—Doxorubicin—thyroid cancer	0.000425	0.00108	CcSEcCtD
Furosemide—CA4—Metabolism—MINPP1—thyroid cancer	0.000425	0.00472	CbGpPWpGaD
Furosemide—SLC22A5—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000424	0.00472	CbGpPWpGaD
Furosemide—SLC22A5—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000424	0.00472	CbGpPWpGaD
Furosemide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000424	0.00108	CcSEcCtD
Furosemide—CA1—C-MYB transcription factor network—CCND1—thyroid cancer	0.000423	0.0047	CbGpPWpGaD
Furosemide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000423	0.00108	CcSEcCtD
Furosemide—SLC12A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000421	0.00469	CbGpPWpGaD
Furosemide—Skin disorder—Doxorubicin—thyroid cancer	0.00042	0.00107	CcSEcCtD
Furosemide—Paraesthesia—Epirubicin—thyroid cancer	0.000419	0.00107	CcSEcCtD
Furosemide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000418	0.00107	CcSEcCtD
Furosemide—Somnolence—Epirubicin—thyroid cancer	0.000415	0.00106	CcSEcCtD
Furosemide—CA9—Cellular responses to stress—EPO—thyroid cancer	0.000414	0.0046	CbGpPWpGaD
Furosemide—Anorexia—Doxorubicin—thyroid cancer	0.000412	0.00105	CcSEcCtD
Furosemide—CA2—Metabolism—MINPP1—thyroid cancer	0.000407	0.00453	CbGpPWpGaD
Furosemide—CA14—Metabolism—HPGD—thyroid cancer	0.000407	0.00453	CbGpPWpGaD
Furosemide—Decreased appetite—Epirubicin—thyroid cancer	0.000406	0.00104	CcSEcCtD
Furosemide—Hypotension—Doxorubicin—thyroid cancer	0.000404	0.00103	CcSEcCtD
Furosemide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000403	0.00103	CcSEcCtD
Furosemide—Fatigue—Epirubicin—thyroid cancer	0.000403	0.00103	CcSEcCtD
Furosemide—Constipation—Epirubicin—thyroid cancer	0.000399	0.00102	CcSEcCtD
Furosemide—Pain—Epirubicin—thyroid cancer	0.000399	0.00102	CcSEcCtD
Furosemide—CA5A—Metabolism—HPGD—thyroid cancer	0.000397	0.00441	CbGpPWpGaD
Furosemide—CA6—Metabolism—HPGD—thyroid cancer	0.000397	0.00441	CbGpPWpGaD
Furosemide—CA1—Metabolism—MINPP1—thyroid cancer	0.00039	0.00434	CbGpPWpGaD
Furosemide—Paraesthesia—Doxorubicin—thyroid cancer	0.000388	0.00099	CcSEcCtD
Furosemide—Feeling abnormal—Epirubicin—thyroid cancer	0.000385	0.000982	CcSEcCtD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000384	0.00427	CbGpPWpGaD
Furosemide—Somnolence—Doxorubicin—thyroid cancer	0.000384	0.00098	CcSEcCtD
Furosemide—SLC22A8—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000384	0.00427	CbGpPWpGaD
Furosemide—SLC22A8—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000384	0.00427	CbGpPWpGaD
Furosemide—PGD—Metabolism—HPGD—thyroid cancer	0.000383	0.00426	CbGpPWpGaD
Furosemide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000382	0.000975	CcSEcCtD
Furosemide—SLC22A11—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000376	0.00419	CbGpPWpGaD
Furosemide—Decreased appetite—Doxorubicin—thyroid cancer	0.000376	0.000959	CcSEcCtD
Furosemide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000373	0.000952	CcSEcCtD
Furosemide—Fatigue—Doxorubicin—thyroid cancer	0.000372	0.000951	CcSEcCtD
Furosemide—Urticaria—Epirubicin—thyroid cancer	0.000371	0.000947	CcSEcCtD
Furosemide—CA5B—Metabolism—HPGD—thyroid cancer	0.00037	0.00412	CbGpPWpGaD
Furosemide—CA7—Metabolism—HPGD—thyroid cancer	0.00037	0.00412	CbGpPWpGaD
Furosemide—Pain—Doxorubicin—thyroid cancer	0.000369	0.000943	CcSEcCtD
Furosemide—Constipation—Doxorubicin—thyroid cancer	0.000369	0.000943	CcSEcCtD
Furosemide—Body temperature increased—Epirubicin—thyroid cancer	0.000369	0.000942	CcSEcCtD
Furosemide—Abdominal pain—Epirubicin—thyroid cancer	0.000369	0.000942	CcSEcCtD
Furosemide—ABCC2—NRF2 pathway—SLC5A5—thyroid cancer	0.000368	0.0041	CbGpPWpGaD
Furosemide—CA1—C-MYB transcription factor network—NRAS—thyroid cancer	0.000364	0.00405	CbGpPWpGaD
Furosemide—CA4—Metabolism—NDUFA13—thyroid cancer	0.000361	0.00402	CbGpPWpGaD
Furosemide—PGD—Disease—TCF7L1—thyroid cancer	0.000359	0.00399	CbGpPWpGaD
Furosemide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000356	0.000909	CcSEcCtD
Furosemide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000353	0.000902	CcSEcCtD
Furosemide—CA2—Metabolism—NDUFA13—thyroid cancer	0.000346	0.00385	CbGpPWpGaD
Furosemide—Hypersensitivity—Epirubicin—thyroid cancer	0.000344	0.000878	CcSEcCtD
Furosemide—Urticaria—Doxorubicin—thyroid cancer	0.000343	0.000876	CcSEcCtD
Furosemide—CA12—Metabolism—HPGD—thyroid cancer	0.000343	0.00382	CbGpPWpGaD
Furosemide—CA9—Metabolism—MINPP1—thyroid cancer	0.000343	0.00382	CbGpPWpGaD
Furosemide—Abdominal pain—Doxorubicin—thyroid cancer	0.000342	0.000872	CcSEcCtD
Furosemide—Body temperature increased—Doxorubicin—thyroid cancer	0.000342	0.000872	CcSEcCtD
Furosemide—CA4—Metabolism—CHST14—thyroid cancer	0.000339	0.00378	CbGpPWpGaD
Furosemide—Asthenia—Epirubicin—thyroid cancer	0.000335	0.000855	CcSEcCtD
Furosemide—CA1—Metabolism—NDUFA13—thyroid cancer	0.000332	0.00369	CbGpPWpGaD
Furosemide—Pruritus—Epirubicin—thyroid cancer	0.00033	0.000843	CcSEcCtD
Furosemide—CA2—Metabolism—CHST14—thyroid cancer	0.000325	0.00362	CbGpPWpGaD
Furosemide—SLCO2A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000323	0.00359	CbGpPWpGaD
Furosemide—SLC12A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000321	0.00357	CbGpPWpGaD
Furosemide—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00032	0.00356	CbGpPWpGaD
Furosemide—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00032	0.00356	CbGpPWpGaD
Furosemide—Diarrhoea—Epirubicin—thyroid cancer	0.000319	0.000815	CcSEcCtD
Furosemide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000318	0.000812	CcSEcCtD
Furosemide—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000317	0.00353	CbGpPWpGaD
Furosemide—CA1—C-MYB transcription factor network—KRAS—thyroid cancer	0.000313	0.00349	CbGpPWpGaD
Furosemide—CA1—Metabolism—CHST14—thyroid cancer	0.000312	0.00347	CbGpPWpGaD
Furosemide—Asthenia—Doxorubicin—thyroid cancer	0.00031	0.000791	CcSEcCtD
Furosemide—ABCC2—NRF2 pathway—RXRA—thyroid cancer	0.000309	0.00344	CbGpPWpGaD
Furosemide—Dizziness—Epirubicin—thyroid cancer	0.000309	0.000788	CcSEcCtD
Furosemide—Pruritus—Doxorubicin—thyroid cancer	0.000306	0.00078	CcSEcCtD
Furosemide—Vomiting—Epirubicin—thyroid cancer	0.000297	0.000758	CcSEcCtD
Furosemide—Diarrhoea—Doxorubicin—thyroid cancer	0.000296	0.000755	CcSEcCtD
Furosemide—Rash—Epirubicin—thyroid cancer	0.000294	0.000751	CcSEcCtD
Furosemide—Dermatitis—Epirubicin—thyroid cancer	0.000294	0.000751	CcSEcCtD
Furosemide—Headache—Epirubicin—thyroid cancer	0.000292	0.000747	CcSEcCtD
Furosemide—CA9—Metabolism—NDUFA13—thyroid cancer	0.000292	0.00324	CbGpPWpGaD
Furosemide—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000287	0.00319	CbGpPWpGaD
Furosemide—Dizziness—Doxorubicin—thyroid cancer	0.000286	0.000729	CcSEcCtD
Furosemide—Nausea—Epirubicin—thyroid cancer	0.000277	0.000708	CcSEcCtD
Furosemide—Vomiting—Doxorubicin—thyroid cancer	0.000275	0.000701	CcSEcCtD
Furosemide—CA9—Metabolism—CHST14—thyroid cancer	0.000274	0.00305	CbGpPWpGaD
Furosemide—CA4—Metabolism—HPGD—thyroid cancer	0.000274	0.00304	CbGpPWpGaD
Furosemide—Rash—Doxorubicin—thyroid cancer	0.000272	0.000695	CcSEcCtD
Furosemide—Dermatitis—Doxorubicin—thyroid cancer	0.000272	0.000695	CcSEcCtD
Furosemide—Headache—Doxorubicin—thyroid cancer	0.000271	0.000691	CcSEcCtD
Furosemide—SLC12A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000269	0.003	CbGpPWpGaD
Furosemide—ABCC2—NRF2 pathway—NRG1—thyroid cancer	0.000268	0.00298	CbGpPWpGaD
Furosemide—CA1—C-MYB transcription factor network—HRAS—thyroid cancer	0.000266	0.00296	CbGpPWpGaD
Furosemide—PGD—Disease—TPR—thyroid cancer	0.000262	0.00292	CbGpPWpGaD
Furosemide—CA2—Metabolism—HPGD—thyroid cancer	0.000262	0.00292	CbGpPWpGaD
Furosemide—PGD—Disease—PRKAR1A—thyroid cancer	0.000258	0.00287	CbGpPWpGaD
Furosemide—Nausea—Doxorubicin—thyroid cancer	0.000257	0.000655	CcSEcCtD
Furosemide—SLC22A11—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000256	0.00284	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—CP—thyroid cancer	0.000256	0.00284	CbGpPWpGaD
Furosemide—CA1—Metabolism—HPGD—thyroid cancer	0.000251	0.0028	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000251	0.0028	CbGpPWpGaD
Furosemide—CA9—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000251	0.00279	CbGpPWpGaD
Furosemide—PGD—Disease—MEN1—thyroid cancer	0.000247	0.00274	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—HIF1A—thyroid cancer	0.000246	0.00274	CbGpPWpGaD
Furosemide—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00024	0.00266	CbGpPWpGaD
Furosemide—CA14—Metabolism—TPR—thyroid cancer	0.000234	0.0026	CbGpPWpGaD
Furosemide—CA14—Metabolism—PRKAR1A—thyroid cancer	0.00023	0.00256	CbGpPWpGaD
Furosemide—CA5A—Metabolism—TPR—thyroid cancer	0.000228	0.00253	CbGpPWpGaD
Furosemide—CA6—Metabolism—TPR—thyroid cancer	0.000228	0.00253	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PRKAR1A—thyroid cancer	0.000224	0.00249	CbGpPWpGaD
Furosemide—CA6—Metabolism—PRKAR1A—thyroid cancer	0.000224	0.00249	CbGpPWpGaD
Furosemide—CA9—Metabolism—HPGD—thyroid cancer	0.000221	0.00246	CbGpPWpGaD
Furosemide—PGD—Metabolism—TPR—thyroid cancer	0.00022	0.00244	CbGpPWpGaD
Furosemide—PGD—Metabolism—PRKAR1A—thyroid cancer	0.000216	0.00241	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000216	0.0024	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—CP—thyroid cancer	0.000216	0.0024	CbGpPWpGaD
Furosemide—CA7—Metabolism—TPR—thyroid cancer	0.000213	0.00237	CbGpPWpGaD
Furosemide—CA5B—Metabolism—TPR—thyroid cancer	0.000213	0.00237	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000212	0.00236	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PRKAR1A—thyroid cancer	0.000209	0.00233	CbGpPWpGaD
Furosemide—CA7—Metabolism—PRKAR1A—thyroid cancer	0.000209	0.00233	CbGpPWpGaD
Furosemide—CA12—Metabolism—TPR—thyroid cancer	0.000197	0.00219	CbGpPWpGaD
Furosemide—PGD—Disease—CALCA—thyroid cancer	0.000196	0.00219	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000195	0.00217	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—CP—thyroid cancer	0.000195	0.00217	CbGpPWpGaD
Furosemide—CA12—Metabolism—PRKAR1A—thyroid cancer	0.000194	0.00216	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000192	0.00213	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000191	0.00213	CbGpPWpGaD
Furosemide—PGD—Disease—CDK1—thyroid cancer	0.000178	0.00198	CbGpPWpGaD
Furosemide—CA14—Metabolism—SLC5A5—thyroid cancer	0.000175	0.00195	CbGpPWpGaD
Furosemide—CA6—Metabolism—SLC5A5—thyroid cancer	0.000171	0.0019	CbGpPWpGaD
Furosemide—CA5A—Metabolism—SLC5A5—thyroid cancer	0.000171	0.0019	CbGpPWpGaD
Furosemide—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000166	0.00185	CbGpPWpGaD
Furosemide—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000166	0.00185	CbGpPWpGaD
Furosemide—PGD—Metabolism—SLC5A5—thyroid cancer	0.000165	0.00183	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000163	0.00181	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	0.000163	0.00181	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000161	0.00179	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000161	0.00179	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00016	0.00178	CbGpPWpGaD
Furosemide—CA7—Metabolism—SLC5A5—thyroid cancer	0.000159	0.00177	CbGpPWpGaD
Furosemide—CA5B—Metabolism—SLC5A5—thyroid cancer	0.000159	0.00177	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000158	0.00175	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000158	0.00175	CbGpPWpGaD
Furosemide—CA4—Metabolism—TPR—thyroid cancer	0.000157	0.00175	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000155	0.00172	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000155	0.00172	CbGpPWpGaD
Furosemide—CA4—Metabolism—PRKAR1A—thyroid cancer	0.000155	0.00172	CbGpPWpGaD
Furosemide—CA2—Metabolism—TPR—thyroid cancer	0.000151	0.00168	CbGpPWpGaD
Furosemide—CA2—Metabolism—PRKAR1A—thyroid cancer	0.000148	0.00165	CbGpPWpGaD
Furosemide—CA12—Metabolism—SLC5A5—thyroid cancer	0.000148	0.00164	CbGpPWpGaD
Furosemide—CA14—Metabolism—RXRA—thyroid cancer	0.000147	0.00164	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000146	0.00162	CbGpPWpGaD
Furosemide—CA1—Metabolism—TPR—thyroid cancer	0.000144	0.00161	CbGpPWpGaD
Furosemide—CA6—Metabolism—RXRA—thyroid cancer	0.000143	0.00159	CbGpPWpGaD
Furosemide—CA5A—Metabolism—RXRA—thyroid cancer	0.000143	0.00159	CbGpPWpGaD
Furosemide—PGD—Disease—NRG1—thyroid cancer	0.000143	0.00159	CbGpPWpGaD
Furosemide—CA1—Metabolism—PRKAR1A—thyroid cancer	0.000142	0.00158	CbGpPWpGaD
Furosemide—PGD—Metabolism—RXRA—thyroid cancer	0.000138	0.00154	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000136	0.00151	CbGpPWpGaD
Furosemide—CA7—Metabolism—RXRA—thyroid cancer	0.000134	0.00149	CbGpPWpGaD
Furosemide—CA5B—Metabolism—RXRA—thyroid cancer	0.000134	0.00149	CbGpPWpGaD
Furosemide—PGD—Disease—TERT—thyroid cancer	0.000128	0.00143	CbGpPWpGaD
Furosemide—CA9—Metabolism—TPR—thyroid cancer	0.000127	0.00141	CbGpPWpGaD
Furosemide—CA9—Metabolism—PRKAR1A—thyroid cancer	0.000125	0.00139	CbGpPWpGaD
Furosemide—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000125	0.00139	CbGpPWpGaD
Furosemide—CA12—Metabolism—RXRA—thyroid cancer	0.000124	0.00138	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000124	0.00138	CbGpPWpGaD
Furosemide—PGD—Disease—HIF1A—thyroid cancer	0.000123	0.00136	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000123	0.00136	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000122	0.00135	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000118	0.00131	CbGpPWpGaD
Furosemide—CA4—Metabolism—SLC5A5—thyroid cancer	0.000118	0.00131	CbGpPWpGaD
Furosemide—CA2—Metabolism—SLC5A5—thyroid cancer	0.000113	0.00125	CbGpPWpGaD
Furosemide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000108	0.0012	CbGpPWpGaD
Furosemide—CA1—Metabolism—SLC5A5—thyroid cancer	0.000108	0.0012	CbGpPWpGaD
Furosemide—ALB—Metabolism—MINPP1—thyroid cancer	0.000107	0.00119	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000102	0.00114	CbGpPWpGaD
Furosemide—PGD—Disease—BRAF—thyroid cancer	0.000102	0.00113	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.91e-05	0.0011	CbGpPWpGaD
Furosemide—CA4—Metabolism—RXRA—thyroid cancer	9.88e-05	0.0011	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—TP53—thyroid cancer	9.8e-05	0.00109	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PRKAR1A—thyroid cancer	9.61e-05	0.00107	CbGpPWpGaD
Furosemide—CA9—Metabolism—SLC5A5—thyroid cancer	9.51e-05	0.00106	CbGpPWpGaD
Furosemide—CA2—Metabolism—RXRA—thyroid cancer	9.48e-05	0.00105	CbGpPWpGaD
Furosemide—CA14—Metabolism—PPARG—thyroid cancer	9.28e-05	0.00103	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TP53—thyroid cancer	9.26e-05	0.00103	CbGpPWpGaD
Furosemide—ALB—Metabolism—NDUFA13—thyroid cancer	9.1e-05	0.00101	CbGpPWpGaD
Furosemide—CA1—Metabolism—RXRA—thyroid cancer	9.08e-05	0.00101	CbGpPWpGaD
Furosemide—CA6—Metabolism—PPARG—thyroid cancer	9.05e-05	0.00101	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PPARG—thyroid cancer	9.05e-05	0.00101	CbGpPWpGaD
Furosemide—PGD—Metabolism—PPARG—thyroid cancer	8.73e-05	0.000971	CbGpPWpGaD
Furosemide—ALB—Metabolism—CHST14—thyroid cancer	8.55e-05	0.000951	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	8.46e-05	0.00094	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	8.46e-05	0.00094	CbGpPWpGaD
Furosemide—CA7—Metabolism—PPARG—thyroid cancer	8.45e-05	0.000939	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PPARG—thyroid cancer	8.45e-05	0.000939	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.32e-05	0.000925	CbGpPWpGaD
Furosemide—PGD—Disease—PTGS2—thyroid cancer	8.2e-05	0.000912	CbGpPWpGaD
Furosemide—CA9—Metabolism—RXRA—thyroid cancer	7.99e-05	0.000888	CbGpPWpGaD
Furosemide—CA12—Metabolism—PPARG—thyroid cancer	7.83e-05	0.00087	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTGS2—thyroid cancer	7.3e-05	0.000812	CbGpPWpGaD
Furosemide—PGD—Disease—PTEN—thyroid cancer	7.15e-05	0.000795	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTGS2—thyroid cancer	7.12e-05	0.000792	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTGS2—thyroid cancer	7.12e-05	0.000792	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGD—thyroid cancer	6.89e-05	0.000767	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTGS2—thyroid cancer	6.87e-05	0.000764	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTGS2—thyroid cancer	6.64e-05	0.000739	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTGS2—thyroid cancer	6.64e-05	0.000739	CbGpPWpGaD
Furosemide—PGD—Disease—NRAS—thyroid cancer	6.38e-05	0.00071	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTEN—thyroid cancer	6.37e-05	0.000708	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IFNA2—thyroid cancer	6.37e-05	0.000708	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.33e-05	0.000704	CbGpPWpGaD
Furosemide—CA4—Metabolism—PPARG—thyroid cancer	6.24e-05	0.000694	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTEN—thyroid cancer	6.21e-05	0.00069	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTEN—thyroid cancer	6.21e-05	0.00069	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTGS2—thyroid cancer	6.16e-05	0.000685	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTEN—thyroid cancer	5.99e-05	0.000666	CbGpPWpGaD
Furosemide—CA2—Metabolism—PPARG—thyroid cancer	5.98e-05	0.000665	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTEN—thyroid cancer	5.8e-05	0.000645	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTEN—thyroid cancer	5.8e-05	0.000645	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARG—thyroid cancer	5.74e-05	0.000638	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.59e-05	0.000622	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—thyroid cancer	5.49e-05	0.000611	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTEN—thyroid cancer	5.37e-05	0.000597	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.32e-05	0.000591	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARG—thyroid cancer	5.04e-05	0.000561	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTGS2—thyroid cancer	4.91e-05	0.000546	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTGS2—thyroid cancer	4.71e-05	0.000523	CbGpPWpGaD
Furosemide—PGD—Disease—HRAS—thyroid cancer	4.67e-05	0.000519	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTGS2—thyroid cancer	4.51e-05	0.000502	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTEN—thyroid cancer	4.28e-05	0.000476	CbGpPWpGaD
Furosemide—PGD—Disease—AKT1—thyroid cancer	4.12e-05	0.000458	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTEN—thyroid cancer	4.1e-05	0.000457	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTGS2—thyroid cancer	3.97e-05	0.000441	CbGpPWpGaD
Furosemide—ALB—Metabolism—TPR—thyroid cancer	3.96e-05	0.00044	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTEN—thyroid cancer	3.94e-05	0.000438	CbGpPWpGaD
Furosemide—ALB—Metabolism—PRKAR1A—thyroid cancer	3.9e-05	0.000433	CbGpPWpGaD
Furosemide—CA14—Metabolism—AKT1—thyroid cancer	3.67e-05	0.000408	CbGpPWpGaD
Furosemide—CA5A—Metabolism—AKT1—thyroid cancer	3.58e-05	0.000398	CbGpPWpGaD
Furosemide—CA6—Metabolism—AKT1—thyroid cancer	3.58e-05	0.000398	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.53e-05	0.000393	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTEN—thyroid cancer	3.46e-05	0.000385	CbGpPWpGaD
Furosemide—PGD—Metabolism—AKT1—thyroid cancer	3.45e-05	0.000384	CbGpPWpGaD
Furosemide—CA5B—Metabolism—AKT1—thyroid cancer	3.34e-05	0.000371	CbGpPWpGaD
Furosemide—CA7—Metabolism—AKT1—thyroid cancer	3.34e-05	0.000371	CbGpPWpGaD
Furosemide—CA12—Metabolism—AKT1—thyroid cancer	3.09e-05	0.000344	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.98e-05	0.000331	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC5A5—thyroid cancer	2.96e-05	0.00033	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.78e-05	0.000309	CbGpPWpGaD
Furosemide—ALB—Metabolism—RXRA—thyroid cancer	2.49e-05	0.000277	CbGpPWpGaD
Furosemide—CA4—Metabolism—AKT1—thyroid cancer	2.47e-05	0.000274	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.42e-05	0.000269	CbGpPWpGaD
Furosemide—ALB—Hemostasis—NRAS—thyroid cancer	2.37e-05	0.000264	CbGpPWpGaD
Furosemide—CA2—Metabolism—AKT1—thyroid cancer	2.37e-05	0.000263	CbGpPWpGaD
Furosemide—CA1—Metabolism—AKT1—thyroid cancer	2.27e-05	0.000252	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—thyroid cancer	2.04e-05	0.000227	CbGpPWpGaD
Furosemide—CA9—Metabolism—AKT1—thyroid cancer	1.99e-05	0.000222	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—thyroid cancer	1.82e-05	0.000202	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HRAS—thyroid cancer	1.74e-05	0.000193	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARG—thyroid cancer	1.57e-05	0.000175	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT1—thyroid cancer	1.53e-05	0.000171	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS2—thyroid cancer	1.24e-05	0.000138	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTEN—thyroid cancer	1.08e-05	0.00012	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKT1—thyroid cancer	6.22e-06	6.91e-05	CbGpPWpGaD
